SCHEMBL23645338

SCHEMBL23645338

CCOC(=O)c1nc2n(c1I)CCCC2

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
ALDH1A1 P00352 6/20 0.53
RAB9A P51151 3/20 0.53
NPC1 O15118 1/20 0.53
KDM4E B2RXH2 3/20 0.49
POLB P06746 2/20 0.49
PDE4A P27815 1/20 0.44
GAA P10253 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
HPGD P15428 2/20 0.40
MAPK1 P28482 1/20 0.40
TP53 P04637 1/20 0.39
ALOX15 P16050 2/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21357773 0.83 MAPT (0.53) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL21357550 0.80 MAPT (0.50) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL21357703 0.80 MAPT (0.50) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL21315297 0.79 POLB (0.53) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL21362977 0.78 MAPT (0.48) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL28626993 0.77 MAPK1 (0.40) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL1421010 0.75 REN (0.48) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL3738019 0.75 POLB (0.62) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL18357419 0.75 POLB (0.58) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL31069250 0.74 TGFBR1 (0.46) MAPTALDH1A1RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2025-09-23 US disclosed
CN-112689636-B Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same 科研制药株式会社 2024-08-20 CN disclosed
EP-3851436-B1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2024-06-12 EP disclosed
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2023-03-23 US disclosed
EP-3851436-A1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2021-07-21 EP disclosed
CN-112689636-A Novel heteroatom aromatic amide derivative and drug containing the same 科研制药株式会社 2021-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A MAPT 4617/4885ALDH1A1 1627/4885RAB9A 1336/4885
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A MAPT 4572/4885ALDH1A1 1596/4885RAB9A 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.